MorphoSys AG Reports First Nine Months and Third Quarter 2022 Financial Results

Monjuvi U.S. net product sales of US$ 22.2 million (€ 21.9 million) for the third quarter of 2022 Presentation of preliminary results from phase 1/2 study of tulmimetostat (CPI-0209) supporting its

Related Keywords

Germany ,Louisiana ,United States ,New Orleans ,United Kingdom ,Planegg ,Bayern ,Massachusetts ,Boston ,Canada ,American ,Monjuvi Minjuvi ,Thomas Biegi ,Tim Demuth ,Julia Neugebauer ,Eamonn Nolan ,Jean Paul Kress ,Md Tim Demuth ,Janssen Biotech Inc ,American Society Of Hematology Annual Meeting ,Xencor Inc ,Linkedin ,Twitter ,Drug Administration ,Nasdaq ,Exchange Commission ,Morphosys Group Key Figures ,Development Rd Expenses ,Share Of Loss Associates ,Society Of Hematologic Oncology ,Chief Executive Officer ,Data Highlights ,Hematologic Oncology ,Molecular Targets ,American Society ,Hematology Annual Meeting ,Chief Research ,Development Officer ,Malte Peters ,Events After ,Third Quarter ,Net Loss ,Royalty Pharma ,Full Year ,Product Sales ,Sys Group Key Figures ,Operating Expenses ,Impairment Losses ,Financial Assets ,Equity Method ,Tax Benefit ,Net Profit ,Antibody Dependent Cell Mediated Cytotoxicity ,Antibody Dependent Cellular Phagocytosis ,Janssen Biotech ,Morphosy Annual Report ,Investor Relations ,Morphosys ,Reports ,First ,Line ,Months ,Third ,Quarter ,022 ,Financial ,Results ,